Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tretinoin

FDA-approved product (solution, topical), marketed as Panretin, Absorica, Absorica Ld and 17 more.

Registered studies
21
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Tretinoin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Acute promyelocytic leukemia
  • Eczematoid dermatitis
  • Freckles
  • Hyperpigmentation of the skin
  • Kaposi's sarcoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Retinoids for topical use in acne; Retinoids for treatment of acne; Agents for dermatitis, excluding corticosteroids; Retinoids for cancer treatment
FDA pharmacologic class
Retinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Tretinoin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tretinoin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tretinoin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

    NCT00124436 · start 2005-03

    Registered record
    Registry ID
    NCT00124436
    Conditions
    Hand Dermatoses
    Interventions
    alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-03
    Completion
    2007-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Dermatoses
    Interventionalitretinoin
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

    NCT00124475 · start 2004-12

    Registered record
    Registry ID
    NCT00124475
    Conditions
    Hand Dermatoses
    Interventions
    alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2007-09
    Enrolment
    1,035

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Dermatoses
    Interventionalitretinoin
    PhasePhase 3
    Registry statusCompleted

  • The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.

    NCT00156169 · start 2001-05

    Registered record
    Registry ID
    NCT00156169
    Conditions
    Low HDL Cholesterol
    Interventions
    Dunaliella
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2006-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow HDL Cholesterol
    InterventionDunaliella
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

    NCT00001504 · start 1996-05

    Registered record
    Registry ID
    NCT00001504
    Conditions
    Breast Cancer; Breast Neoplasm
    Interventions
    9-cis-Retinoic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-05
    Completion
    2002-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Neoplasm
    Intervention9-cis-Retinoic Acid
    PhasePhase 1
    Registry statusCompleted

  • A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma

    NCT00002188

    Registered record
    Registry ID
    NCT00002188
    Conditions
    Sarcoma, Kaposi; HIV Infections
    Interventions
    Alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Kaposi; HIV Infections
    InterventionAlitretinoin
    PhasePhase 2
    Registry statusCompleted

  • A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

    NCT00002439

    Registered record
    Registry ID
    NCT00002439
    Conditions
    Sarcoma, Kaposi; HIV Infections
    Interventions
    Alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Kaposi; HIV Infections
    InterventionAlitretinoin
    PhaseNot applicable
    Registry statusCompleted